Since 2016, all the major steps in the development of TOTUM•63 have been the subject of a communication at the prestigious scientific sessions of the American Diabetes Association. It is now the turn of the vast Phase II/III REVERSE-IT clinical study, carried out in partnership with Nestlé Health Science, to be selected for this 83rd edition, which takes place from 23 to 26 June in San Diego. Valbiotis is proud to present the design and characteristics of the population at baseline of the REVERSE-IT study, one of the most extensive study carried out on early dysglycemia with a nutritional approach.
See poster 